Selecting here opens the current stored cards. The pinned link below records their fingerprints. Do not enter patient information in links or searches.
Share or print this source review
1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.
Copy is optional; the link can be selected and copied manually. No patient data or dose decision is collected.
Clinical context remains essential
Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.
Check source scope before reading a dose
Baclofen toxicity in kidney disease - case-based expert recommendations
Product / population
Baclofen toxicity in kidney disease - case-based expert recommendations; selected source sections only, not a complete prescribing monograph.
Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.
Documented differences and cautions on this drug
All record notes are retained here, including notes about sources not selected in this review.
Baclofen: qualitative label caution versus case-based avoidance guidance
The OZOBAX label gives no numerical cutoff. Wolf et al. recommend reduction in moderate dysfunction and avoidance in severe dysfunction or renal replacement therapy, based on case-based expert interpretation.
What to reconcile: Attribute the literature recommendation and evidence limits. Do not invent a reduction percentage or describe it as a product-specific trial.
Wolf et al. / American Journal of Kidney Diseases · Baclofen toxicity in kidney disease - case-based expert recommendations; selected source sections only, not a complete prescribing monograph.
Professional guidance with defined scope. Publication date, institutional setting and source limitations remain controlling. This is not automatic preference over another source.
Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.
Renal dosing, restrictions and evidence limits
Wolf and colleagues recommend reducing baclofen in eGFR 30-60 mL/min/1.73 m2 and avoiding it below 30 or during renal replacement therapy. Their teaching case describes severe toxicity in a hemodialysis patient. This is case-based expert guidance, not an OZOBAX-specific trial or a validated numerical dose table. The abstract does not specify a reduction percentage; none is supplied here.
This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.
GlobalRPh v6.6 | RDM66-DIRECT-PHP-20260911 | Local library date 2026-09-11. Selected-card identity does not imply clinical verification.